# Immunomic Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunomic-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Rockville, US
- Website: www.immunomix.com
- Total disclosed funding: $0.6M
- Latest round: Series A (Mar 1, 2010)
- Investors on record: 4

## About

Immunomic Therapeutics, Inc. focuses on advancing innovative immunotherapies, employing its unique UNITE® platform to enhance immune responses against cancers and allergies, contributing to the field of personalized medicine.Immunomic Therapeutics, Inc. was founded in 2005 in Rockville, US, and specializes in developing immunotherapeutic vaccines. The company has undergone strategic pivots focusing on the therapeutic application of its UNITE® platform in oncology. Under the leadership of CEOs Dong-Gun Kim and William Hearl, the firm has successfully raised a total of USD 51.30 mn from multiple funding rounds, with the most recent round occurring on April 23, 2020, led by Hlb Co., Ltd. The company has completed a total of 11 deals to date.Immunomic Therapeutics, Inc. specializes in developing innovative vaccines through its proprietary UNITE® platform, which enhances immune responses to combat various cancers and allergies. Its primary products include ITI-1001, targeting cytomegalovirus (CMV)-associated antigens in newly diagnosed Glioblastoma Multiforme (GBM), and ITI-1771, aimed at treating CMV-driven cancers. Additional offerings are ITI-5000 for Triple Negative Breast Cancer, ITI-9001 for Japanese Red Cedar Allergy, ITI-8000 as a next-generation checkpoint inhibitor, and ITI-2000 for HPV+ tumors related to head and neck cancers. These products stimulate specific immune responses, aiming to enhance anti-tumor capabilities, with ongoing clinical trials in collaboration with institutions like the Dana Farber Cancer Institute.Immunomic Therapeutics operates within a clinical development framework focused on its pipeline of immunotherapeutic products. Revenue is primarily generated through partnerships and collaborations with research institutions, alongside licensing agreements for its technologies. The firm's flagship products, including ITI-1001, are positioned within clinical trials that may lead to future revenue streams upon successful commercialization and regulatory approvals. The company engages with a diverse client base, encompassing oncologists, cancer treatment centers, and research organizations dedicated to innovative cancer therapies.Immunomic Therapeutics plans to utilize the USD 51.30 mn raised in its April 2020 funding to support the advancement of its product pipeline and expand research efforts. The company is focused on launching new products and may seek to enter new geographical markets, specifically targeting regions in Europe and Asia by 2023. The funding will bolster its research capabilities, facilitating clinical trials and potential collaborations that enhance its competitive positioning in the immunotherapy market.

## Funding rounds

- Series A, Mar 1, 2010, $0.6M — Life Sciences Greenhouse of Central Pennsylvania, Minority Angel Investor Network, Brainchild Holdings
- Seed, Feb 1, 2007 — TCP Venture Capital

## Investors

- TCP Venture Capital (https://capitalatlas.ai/funds/tcp-venture-capital) — Seed
- Life Sciences Greenhouse of Central Pennsylvania — Series A
- Minority Angel Investor Network — Series A
- Brainchild Holdings (https://capitalatlas.ai/funds/brainchild-holdings) — Series A